Jefferies Top Drug Stocks for the Rest of 2016
For the most part, Jefferies maintained its list of top companies in the health care sector, but it also made a couple additions and updated its price target information.
All Work
Chris Lange
Solazyme Stuns Investors With Bottom Line Beat
Solazyme reported mixed fourth-quarter financial results and a deal with Unilever after the markets closed on Monday.
What to Look for in Oracle Earnings
Oracle is scheduled to report its fiscal third-quarter financial results after the markets close on Tuesday.
SEC Settles Charges With Texas Company for Faulty Evaluations of Internal Controls
The SEC has settled charges against Texas-based oil company Magnum Hunter Resources and several individuals for deficient evaluation of the company’s internal controls over financial reporting.
Vericel Trips Over Earnings
Vericel Corp. (NASDAQ: VCEL) reported its fourth-quarter financial results before the markets opened on Monday. The company said it had a net loss of $0.28 per share on $15.4 million in revenue, which compares…
How AMD Is Taking Over Virtual Reality
AMD made waves in the market Monday morning following its presentation at the 2016 Game Developer Conference.
SEC Announces Fraud Charges on California Man
The SEC has announced fraud charges against a California businessman accused of stealing investor assets and then trying to cover it up once the SEC caught onto his scheme.
Senseonics Gears Up for IPO
Senseonics Holdings has filed an amended S-1 form with the U.S. Securities and Exchange Commission (SEC) regarding its initial public offering (IPO). No pricing details were given in the filing for the 18.2 million shares with…
SEC Charges Oregon Firm With Defrauding Investors
The SEC has charged an Oregon-based investment group and three top executives with hiding the rapidly deteriorating financial condition of its enterprise while raising millions from investors.
What to Expect From Valeant Pharma Q4 Earnings
Valeant Pharmaceuticals is scheduled to report its fourth-quarter preliminary results and update its 2016 financial guidance in a conference call Tuesday morning.
GW Pharma Explodes on Positive Late-Stage Results
GW Pharmaceuticals has announced the positive results of the first pivotal Phase 3 study of its investigational medicine Epidiolex for the treatment of Dravet syndrome.
5 Key Earnings for the Week Ahead
24/7 Wall St. has put together a preview of FedEx, Oracle and some of the other major companies reporting their quarterly results this coming week.
5 Key FDA Decisions Expected in March
24/7 Wall St. has collected three big FDA decisions coming up in March and added some color, along with the trading range and price target.
Analysts Make Big Changes on Cybersecurity Stock Ratings
Recent analyst calls on some major companies in the cybersecurity field offer a picture of what analysts see in the industry and where it could stand to go in the coming months.
6 Top Companies That Destroyed Shareholders Last Week
Although stocks now are beginning to make a comeback, there are still some that are slowing this recovery and punishing their shareholders.
Analysts Much More Excited About Finisar After Solid Earnings
Analysts and investors alike were thrilled with Finisar's fiscal third-quarter financial results and pushed the stock up nearly 20% on Friday.
Finisar Wows With Guidance
Finisar reported mixed fiscal third-quarter financial results after the markets closed on Thursday.
3M Partners Up With Nobel
3M will collaborate with Nobel Media over several years to bring light to important global issues, like the future of scientific education and sustainability.
Regeneron Scores Win in Late-Stage Rheumatoid Arthritis Trial
Regeneron Pharmaceuticals Inc. (NASDAQ: REGN) scored a win in a late-stage trial for the treatment of rheumatoid arthritis (RA). The company, in conjunction with Sanofi, announced that a Phase 3 monotherapy study met its…
SEC Charges Tech Company With Misleading Investors
The SEC has announced that a developer of technologies for touchscreen devices has agreed to pay $750,000 to settle charges that it misled investors.